Adi Gilboa-Geffen
Chief Executive Officer ScionxBio
Seminars
Wednesday 22nd July 2026
xRNA Unlocking the Therapeutic Potential of mRNA
12:20 pm
- Scionxbio develops a modality called xRNA, which is a synthetic mRNA that utilizes precisely positioned, noncanonical building blocks to resist degradation, increase protein production, and minimize immunogenicity
- The outcome is a robust and long-lasting therapeutic effect. A proprietary high-throughput platform facilitates systematic screening of xRNAs and derivation of AI-enabled StructureActivity-Relationships (SARs)
- Our hit optimization pipeline of screening, in vitro confirmation, and in vivo validation demonstrated broad utility
